BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28512310)

  • 1. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible.
    Grabner A; Schramm K; Silswal N; Hendrix M; Yanucil C; Czaya B; Singh S; Wolf M; Hermann S; Stypmann J; Di Marco GS; Brand M; Wacker MJ; Faul C
    Sci Rep; 2017 May; 7(1):1993. PubMed ID: 28512310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypericin Alleviates Chronic Kidney Disease-induced Left Ventricular Hypertrophy by Regulation of FGF23-FGFR4 Signaling Pathway.
    Liu M; Cheng L; Ye Q; Liu H; Shu C; Gao H; Liu X; Zhang X; Chen G
    J Cardiovasc Pharmacol; 2024 Jun; 83(6):588-601. PubMed ID: 38547517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.
    Leifheit-Nestler M; Grabner A; Hermann L; Richter B; Schmitz K; Fischer DC; Yanucil C; Faul C; Haffner D
    Nephrol Dial Transplant; 2017 Sep; 32(9):1493-1503. PubMed ID: 28339837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.
    Grabner A; Amaral AP; Schramm K; Singh S; Sloan A; Yanucil C; Li J; Shehadeh LA; Hare JM; David V; Martin A; Fornoni A; Di Marco GS; Kentrup D; Reuter S; Mayer AB; Pavenstädt H; Stypmann J; Kuhn C; Hille S; Frey N; Leifheit-Nestler M; Richter B; Haffner D; Abraham R; Bange J; Sperl B; Ullrich A; Brand M; Wolf M; Faul C
    Cell Metab; 2015 Dec; 22(6):1020-32. PubMed ID: 26437603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice.
    Han X; Cai C; Xiao Z; Quarles LD
    J Mol Cell Cardiol; 2020 Jan; 138():66-74. PubMed ID: 31758962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
    Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner.
    Graves JM; Vallejo JA; Hamill CS; Wang D; Ahuja R; Patel S; Faul C; Wacker MJ
    Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2283-H2294. PubMed ID: 33929896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGF23 induces left ventricular hypertrophy.
    Faul C; Amaral AP; Oskouei B; Hu MC; Sloan A; Isakova T; Gutiérrez OM; Aguillon-Prada R; Lincoln J; Hare JM; Mundel P; Morales A; Scialla J; Fischer M; Soliman EZ; Chen J; Go AS; Rosas SE; Nessel L; Townsend RR; Feldman HI; St John Sutton M; Ojo A; Gadegbeku C; Di Marco GS; Reuter S; Kentrup D; Tiemann K; Brand M; Hill JA; Moe OW; Kuro-O M; Kusek JW; Keane MG; Wolf M
    J Clin Invest; 2011 Nov; 121(11):4393-408. PubMed ID: 21985788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the implications of blocking renin-angiotensin-aldosterone system and fibroblast growth factor 23 in early left ventricular hypertrophy without chronic kidney disease.
    Watanabe K; Fujii H; Okamoto K; Kono K; Goto S; Nishi S
    Front Endocrinol (Lausanne); 2023; 14():1276664. PubMed ID: 38174329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGFR4 does not contribute to progression of chronic kidney disease.
    Taylor A; Yanucil C; Musgrove J; Shi M; Ide S; Souma T; Faul C; Wolf M; Grabner A
    Sci Rep; 2019 Oct; 9(1):14023. PubMed ID: 31575945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct and indirect effects of fibroblast growth factor 23 on the heart.
    Nakano T; Kishimoto H; Tokumoto M
    Front Endocrinol (Lausanne); 2023; 14():1059179. PubMed ID: 36909314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective Effects of Paricalcitol Alone and in Combination With FGF23 Receptor Inhibition in Chronic Renal Failure: Experimental and Clinical Studies.
    Czaya B; Seeherunvong W; Singh S; Yanucil C; Ruiz P; Quiroz Y; Grabner A; Katsoufis C; Swaminathan S; Abitbol C; Rodriguez-Iturbe B; Faul C; Freundlich M
    Am J Hypertens; 2019 Jan; 32(1):34-44. PubMed ID: 30329020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S100a8/9 (S100 Calcium Binding Protein a8/9) Promotes Cardiac Hypertrophy Via Upregulation of FGF23 (Fibroblast Growth Factor 23) in Mice.
    Yuan YP; Shen ZY; Teng T; Xu SC; Kong CY; Zeng XF; A Hofmann Bowman M; Yan L
    J Am Heart Assoc; 2024 May; 13(10):e028006. PubMed ID: 38726894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast Growth Factor (FGF) 23 and FGF Receptor 4 promote cardiac metabolic remodeling in chronic kidney disease.
    Fuchs MA; Burke EJ; Latic N; Murray S; Li H; Sparks M; Abraham D; Zhang H; Rosenberg P; Hänzelmann S; Hausmann F; Huber T; Erben R; Fisher-Wellman K; Bursac N; Wolf M; Grabner A
    Res Sq; 2023 Dec; ():. PubMed ID: 38196615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF23-Mediated Activation of Local RAAS Promotes Cardiac Hypertrophy and Fibrosis.
    Böckmann I; Lischka J; Richter B; Deppe J; Rahn A; Fischer DC; Heineke J; Haffner D; Leifheit-Nestler M
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31540546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.
    Di Marco GS; Reuter S; Kentrup D; Grabner A; Amaral AP; Fobker M; Stypmann J; Pavenstädt H; Wolf M; Faul C; Brand M
    Nephrol Dial Transplant; 2014 Nov; 29(11):2028-35. PubMed ID: 24875663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic background influences cardiac phenotype in murine chronic kidney disease.
    Neuburg S; Dussold C; Gerber C; Wang X; Francis C; Qi L; David V; Wolf M; Martin A
    Nephrol Dial Transplant; 2018 Jul; 33(7):1129-1137. PubMed ID: 29309658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease.
    Singh S; Grabner A; Yanucil C; Schramm K; Czaya B; Krick S; Czaja MJ; Bartz R; Abraham R; Di Marco GS; Brand M; Wolf M; Faul C
    Kidney Int; 2016 Nov; 90(5):985-996. PubMed ID: 27457912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac Fibroblast Growth Factor 23 Excess Does Not Induce Left Ventricular Hypertrophy in Healthy Mice.
    Leifheit-Nestler M; Wagner MA; Richter B; Piepert C; Eitner F; Böckmann I; Vogt I; Grund A; Hille SS; Foinquinos A; Zimmer K; Thum T; Müller OJ; Haffner D
    Front Cell Dev Biol; 2021; 9():745892. PubMed ID: 34778257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor 23 and the heart.
    Faul C
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):369-75. PubMed ID: 22531163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.